公开(公告)号：US5489303A

公开(公告)日：1996-02-06

申请号：US200569

申请日：1994-02-22

申请人： Masatomi Sasaki ,  Hiroki Sakakibara ,  Makoto Saruhashi ,  Shinichi Tategami

发明人： Masatomi Sasaki ,  Hiroki Sakakibara ,  Makoto Saruhashi ,  Shinichi Tategami

IPC分类号： A61L33/00 ,  B01D67/00 ,  C08G65/332 ,  A61F2/02 ,  A61F2/06

CPC分类号： B01D67/0093 ,  A61L33/0005 ,  A61L33/0082 ,  C08G65/3322 ,  B01D2323/38

摘要： A medical material which comprises an oil-soluble vitamin hydrophobically bound to a hydrophobic moiety containing macromer which is bound to the surface of a polymeric substrate via a copolymer is described. Suitable macromers include for example glycidyl methacrylate-linoleic acid. Suitable polymeric substrate materials include, in particular, cellulose. Methods for producing said medical material are also provided.

摘要翻译： 描述了包含与通过共聚物结合到聚合物基材的表面的含疏水部分的大分子单体疏水结合的油溶性维生素的医疗材料。 合适的大分子单体包括例如甲基丙烯酸缩水甘油酯 - 亚油酸。 合适的聚合物基材包括，特别是纤维素。 还提供了生产所述医疗材料的方法。

公开(公告)号：US6001288A

公开(公告)日：1999-12-14

申请号：US997825

申请日：1997-12-24

申请人： Makoto Saruhashi ,  Masatomi Sasaki

发明人： Makoto Saruhashi ,  Masatomi Sasaki

IPC分类号： B01D69/08 ,  B29C65/00

CPC分类号： B01D69/08

摘要： A process for producing a hollow fiber membrane, a hollow fiber membrane, and a dialyzer of hollow fiber membrane type is provided. The hollow fiber membrane is highly biocompatible, and the production process is quite simple and inexpensive. In the process of the invention, the hollow fiber membrane is produced in a system wherein a polymer-containing spinning solution is extruded from a tube-in-tube type orifice of a spinner in a coagulation solution to form the hollow fiber membrane. The polymer-containing spinning solution is extruded from the outer tube of the orifice to form a cylindrical filament having an inner bore and a core solution is ejected from the inner tube of the orifice into the inner bore of the filament for coagulation of the filament. The filament is directly extruded into the coagulation solution or extruded into air and then drawn to the coagulation solution. The core solution is supplemented with a hydrophobic modifier such as vitamin E and a surfactant and the resulting hollow fiber membrane contains the hydrophobic modifier on its inner surface.

摘要翻译： 提供了中空纤维膜型中空纤维膜，中空纤维膜和透析器的制造方法。 中空纤维膜具有高生物相容性，生产工艺相当简单，成本低廉。 在本发明的方法中，中空纤维膜在其中将含聚合物的纺丝溶液从凝结溶液中的旋转管的管中管孔挤出以形成中空纤维膜的系统中制造。 含有聚合物的纺丝溶液从孔的外管挤出形成具有内孔的圆柱形细丝，并且核心溶液从孔口的内管喷射到丝的内孔中，以使细丝凝结。 将细丝直接挤入凝固溶液中或挤出至空气中，然后拉至凝固溶液。 核心溶液补充有疏水改性剂如维生素E和表面活性剂，所得中空纤维膜在其内表面上含有疏水改性剂。

公开(公告)号：US5160672A

公开(公告)日：1992-11-03

申请号：US358618

申请日：1989-05-30

申请人： Masatomi Sasaki ,  Nobuyoshi Kashiwagi ,  Hiroki Sakakibara ,  Makoto Saruhashi

发明人： Masatomi Sasaki ,  Nobuyoshi Kashiwagi ,  Hiroki Sakakibara ,  Makoto Saruhashi

IPC分类号： B01D67/00 ,  A61M1/18 ,  B01D69/08 ,  B01D71/10 ,  D01D5/24 ,  D01F2/04 ,  D01F6/00

CPC分类号： D01D5/24 ,  B01D69/08

摘要： A method for the production of a hollow fiber membrane by the steps of discharging a spinning dope through an annular spinning nozzle and, at the same time, introducing a non-coagulating liquid for the spinning dope into the central cavity in a hollow fiber of the spinning dope being discharged, and then introducing the discharged fiber of the spinning dope into a coagulating liquid thereby solidifying the discharged fiber into a hollow fiber membrane, which method is characterized by incorporating a surface modifying agent in said non-coagulating liquid thereby modifying the inner surface behavior of the produced hollow fiber membrane.

公开(公告)号：US5084349A

公开(公告)日：1992-01-28

申请号：US403354

申请日：1989-09-06

申请人： Masatomi Sasaki ,  Hirotomo Morita ,  Hiroki Sakakibara ,  Makoto Saruhashi ,  Yutaka Matsumoto

发明人： Masatomi Sasaki ,  Hirotomo Morita ,  Hiroki Sakakibara ,  Makoto Saruhashi ,  Yutaka Matsumoto

IPC分类号： B01D69/02 ,  B01D69/08 ,  B01D71/10

CPC分类号： B01D69/02 ,  B01D69/08 ,  B01D71/10 ,  Y10T428/2935 ,  Y10T428/2975

摘要： The cellulosic hollow-fiber membranes of the invention are useful in fluid processing apparatus typically for artificial dialysis. Each fiber has a tubular microporous wall having micropores and defining a lumen. The micropores have an average pore diameter of about 55 to about 300 .ANG.. The cellulosic hollow fibers exhibit a percent removal of .beta..sub.2 -microglobulin through adsorption of up to 10% after a solution of 20 mg/l of .beta..sub.2 -microglobulin in water is circulated through the fiber lumen for 3 hours. They also exhibit a sufficient filtration fraction of .beta..sub.2 -microglobulin and a ultrafiltration rate to remove .beta..sub.2 -microglobulin from blood predominantly through filtration while preventing contamination of the membranes with .beta..sub.2 -microglobulin due to adsorption and controlling the amount of water removed from the blood. The fibers are prepraed by wet spinning a cellulosic spinning dope into a hollow fiber followed by washing, heat treatment, plasticizing, and drying.

公开(公告)号：US20120191102A1

公开(公告)日：2012-07-26

申请号：US13433534

申请日：2012-03-29

申请人： Atsushi MATSUMOTO ,  Makoto Saruhashi

发明人： Atsushi MATSUMOTO ,  Makoto Saruhashi

IPC分类号： A61B17/58

CPC分类号： A61M5/14526 ,  A61B17/8822 ,  A61B2017/00539 ,  A61M5/31511

摘要： A medicine injection device includes a medicine ejection unit having a fluid flow-in port for receiving liquid, and a pressure generation unit which includes a pressure generating chamber to generate pressure acting upon a working chamber of the medicine ejection unit through the liquid and which ejects medicine by moving a gasket based on the applied pressure. The pressure generation unit includes a pressure portion cylinder in the pressure generating chamber, a first pusher provided with a hollow gasket defining the inner volume of the pressure generating chamber and a second pusher which generates the pressure inside the pressure generating chamber by pressing a distal end head portion into the inside of the pressure generating chamber. The pressure portion cylinder and the first pusher are coupled through an engagement mechanism in which fixation and fixation release are possible at different pitches in the axial direction.

摘要翻译： 药剂注射装置包括具有用于接收液体的流体流入口的药物喷射单元和压力产生单元，该压力产生单元包括通过液体产生作用在药物喷射单元的工作室上的压力的压力产生室， 基于所施加的压力移动垫圈来治疗药物。 压力发生单元包括在压力发生室中的压力部分气缸，第一推动器设置有限定压力产生室的内部容积的中空衬垫，以及第二推动器，其通过压迫压力产生室的远端产生压力 头部进入压力发生室的内部。 压力部分气缸和第一推动器通过接合机构联接，其中在轴向上以不同的间距可以进行固定和固定释放。

公开(公告)号：US20110202065A1

公开(公告)日：2011-08-18

申请号：US13124579

申请日：2009-10-16

申请人： Kenji Takizawa ,  Koichi Hayakawa ,  Takuya Uno ,  Makoto Saruhashi

发明人： Kenji Takizawa ,  Koichi Hayakawa ,  Takuya Uno ,  Makoto Saruhashi

IPC分类号： A61B17/58

CPC分类号： A61B17/3472 ,  A61B17/8827

摘要： A bone cement injection needle comprises: a hollow outer needle; an outer needle hub affixed to the base end part of the outer needle; an inner needle that can be slidably inserted into the hollow part of the outer needle; and an inner needle hub affixed to the base end part of the inner needle. The outer needle comprises a first side hole located near the tip; a second side hole located near the base end part; and a depressurization passage which connects the first side hole and the second side hole.

摘要翻译： 骨水泥注射针包括：中空外针; 固定在外针的基端部的外针毂; 能够滑动地插入外针的中空部的内针; 以及固定在内针的基端部的内针毂。 外针包括位于尖端附近的第一侧孔; 位于所述基端部附近的第二侧孔; 以及连接第一侧孔和第二侧孔的减压通路。

公开(公告)号：US06478960B1

公开(公告)日：2002-11-12

申请号：US09213871

申请日：1998-12-17

申请人： Makoto Saruhashi ,  Masatomi Sasaki

发明人： Makoto Saruhashi ,  Masatomi Sasaki

IPC分类号： B01D6302

CPC分类号： B01D67/0088 ,  A61M1/16 ,  A61M1/1627 ,  B01D63/021 ,  B01D69/08

摘要： A manufacturing method of an artificial organ formed of a material having a solubility parameter &dgr; of not more than 13 (cal/cm3)½ involves filling micropores of the body fluid treatment membrane with a filling solution having no or little solubility with respect to a fat-soluble modifier solution, and coating a portion of the body fluid treatment membrane with the fat-soluble modifier by contacting the fat-soluble modifier solution. With this method substantially only the necessary portions need to be coated with the fat-soluble modifier so that a smaller amount of the fat-soluble modifier may be employed. A microporous membrane is formed of a synthetic polymer substrate having a solubility parameter &dgr; of not more than 13 (cal/cm3)½, with not less than 50 wt % of fat-soluble modifier included in the hollow fiber membrane being held on a surface which may contact body fluid. The membrane possesses the following sieve coefficients measured by dextrans: no more than 0.4 when a dextran with a molecular weight of 100,000 is employed; and not less than 0.5 when another dextran with a molecular weight of 10,000 is employed.

摘要翻译： 由溶解度参数δ不大于13（cal / cm 3）1/2的材料形成的人造器官的制造方法涉及用相对于脂肪不溶或溶解度小的填充溶液填充体液处理膜的微孔 并且通过使脂溶性改性剂溶液接触，用脂溶性改性剂涂覆一部分体液处理膜。 使用该方法基本上仅需要涂覆脂溶性改性剂所需的部分，从而可以使用较少量的脂溶性改性剂。 微孔膜由溶解度参数δ不大于13（cal / cm 3）1/2的合成聚合物基材形成，中空纤维膜中包含的不少于50重量％的脂溶性改性剂被保持在表面上 其可以接触体液。 该膜具有由葡聚糖测定的以下筛分系数：当使用分子量为100,000的葡聚糖时不超过0.4; 并且当使用分子量为10,000的另一个葡聚糖时不小于0.5。